Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic

Jorge A. R. Salvador, Vania M. Moreira, Samuel M. Silvestre

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.
LanguageEnglish
Title of host publicationAdvances in Prostate Cancer
Place of PublicationLondon
Pages275-304
Number of pages30
DOIs
Publication statusPublished - 16 Jan 2013

Fingerprint

exemestane
Lyases
Mixed Function Oxygenases
Cytochrome P-450 Enzyme System
Androgens
Prostatic Neoplasms
Aromatase Inhibitors
Aromatase
Castration
Androgen Receptors
Growth Hormone
Prostate
Adrenal Cortex Hormones
Estrogens
Cell Proliferation
Hormones
Breast Neoplasms
Growth
Neoplasms
Proteins

Keywords

  • CYP17
  • CYP17 inhibitors
  • prostate cancer treatment

Cite this

Salvador, J. A. R., Moreira, V. M., & Silvestre, S. M. (2013). Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic. In Advances in Prostate Cancer (pp. 275-304). London. https://doi.org/10.5772/52290
Salvador, Jorge A. R. ; Moreira, Vania M. ; Silvestre, Samuel M. / Steroidal CYP17 inhibitors for prostate cancer treatment : from concept to clinic. Advances in Prostate Cancer. London, 2013. pp. 275-304
@inbook{f84de5623a84404f951ce08ed70aaa09,
title = "Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic",
abstract = "The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.",
keywords = "CYP17 , CYP17 inhibitors, prostate cancer treatment",
author = "Salvador, {Jorge A. R.} and Moreira, {Vania M.} and Silvestre, {Samuel M.}",
year = "2013",
month = "1",
day = "16",
doi = "10.5772/52290",
language = "English",
isbn = "978-953-51-0932-7",
pages = "275--304",
booktitle = "Advances in Prostate Cancer",

}

Salvador, JAR, Moreira, VM & Silvestre, SM 2013, Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic. in Advances in Prostate Cancer. London, pp. 275-304. https://doi.org/10.5772/52290

Steroidal CYP17 inhibitors for prostate cancer treatment : from concept to clinic. / Salvador, Jorge A. R.; Moreira, Vania M.; Silvestre, Samuel M.

Advances in Prostate Cancer. London, 2013. p. 275-304.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Steroidal CYP17 inhibitors for prostate cancer treatment

T2 - from concept to clinic

AU - Salvador, Jorge A. R.

AU - Moreira, Vania M.

AU - Silvestre, Samuel M.

PY - 2013/1/16

Y1 - 2013/1/16

N2 - The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.

AB - The successful application of therapeutic strategies to block the known growth stimulation property of estrogen in breast cancer, namely the aromatase (CYP19) inhibitors formestane (4-OH) and exemestane (Aromasin) [1], has paved the way for the investigation of inhibitors of other P450 enzymes that might impart the growth of hormone-dependent cancers [2]. Cytochrome P450 17α-hydroxylase,C17,20-lyase (CYP17) is at the crossroads of androgen and corticoid biosynthesis and has become a valuable target in prostate cancer (PC) treatment [3-8]. Androgens, which are produced in steroidogenic tissues, bind to the androgen receptor (AR) and initiate transcription which in turn results in the synthesis of prostate-specific proteins, as well as in cell proliferation. Systemic ablation of androgen by castration, either surgical or chemical, is highly effective in treating PC when the disease is hormone-dependent.

KW - CYP17

KW - CYP17 inhibitors

KW - prostate cancer treatment

U2 - 10.5772/52290

DO - 10.5772/52290

M3 - Chapter

SN - 978-953-51-0932-7

SP - 275

EP - 304

BT - Advances in Prostate Cancer

CY - London

ER -

Salvador JAR, Moreira VM, Silvestre SM. Steroidal CYP17 inhibitors for prostate cancer treatment: from concept to clinic. In Advances in Prostate Cancer. London. 2013. p. 275-304 https://doi.org/10.5772/52290